In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Johnson Matthey Plc

http://www.matthey.com/

Latest From Johnson Matthey Plc

Novo Ventures Remains Bullish After ‘Very Active’ Year

In this latest installment of VC playbook, In Vivo speaks to Naveed Siddiqi, senior partner at Novo Ventures. He discusses the group’s strategy, the European investment outlook for life sciences and how COVID-19 has permanently shifted perceptions of the biopharma industry.

VC Playbook Business Strategies

Deal Watch: Roche Links With SemaThera, Acquires GenMark Diagnostics

Tempest goes public via a reverse merger with Millendo. Takeda inks its ninth deal of 2021, a discovery pact with BridGene around its chemoproteomics technology.

Deals Business Strategies

Spain's Highlight Has High Hopes For Immuno-Oncology Agent

After a decade of research, the Spanish biotech believes its lead candidate BO-112 can turn ‘cold’ tumors ‘hot,' offering the potential to rescue patients who are resistant to current checkpoint inhibitor therapy.

StartUps and SMEs ImmunoOncology

Revamped Modus Switches To Sepsis, Septic Shock For Sevuparin

After disappointment in sickle cell anemia, Modus Therapeutics will now develop its lead asset sevuparin as a treatment for sepsis and septic shock and plans a public listing in Sweden to fund the new strategy, its CEO tells Scrip.

Clinical Trials Companies
See All

Company Information

  • Industry
  • Diversified
  • Pharmaceuticals
UsernamePublicRestriction

Register